Insulin volume growth (full year)
+6%
+6% YoY
Overall insulin volume growth for FY25, driven by Toujeo and Soliqua.
SANOFIINDIA
Diversified
10 Feb 2026
Sanofi India Ltd — Q3 FY26
Sanofi India reported a mixed Q4 FY26 with domestic sales of ₹1,511 crore for FY25, driven by 11% YoY growth in the diabetes segment, led by insulin portfolio (Lantus, Toujeo, Soliqua).
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Sanofi India reported a mixed Q4 FY26 with domestic sales of ₹1,511 crore for FY25, driven by 11% YoY growth in the diabetes segment, led by insulin portfolio (Lantus, Toujeo, Soliqua). However, partnership revenue declined sharply to ₹153 crore in Q4 from ₹200 crore in Q3 due to inventory phasing and a frozen period. PAT grew 4% YoY for the full year, but EBITDA margin fell to 21.5%, an eight-quarter low, impacted by export decline and partnership volatility. Management expects partnership fluctuations to continue through FY26, with stabilization by year-end. Diabetes growth remains robust, with insulin volume accelerating +6% overall and +11% in Q4. Key risk: continued partnership revenue volatility could mask underlying business performance.
Key Numbers
Insulin volume growth (Q4)
+11%
+11% YoY
Accelerated momentum in Q4, indicating recovery from transformation.
Partnership revenue (Q4)
₹153 crore
-24% QoQ
Sharp drop from ₹200 crore in Q3 due to inventory phasing and frozen period.
Lantus market share (basal segment)
31%
flat YoY
Continued leadership in basal insulin segment despite GLP-1 competition.
Management Guidance
Partnership revenue fluctuations to continue through FY26
Management expects inventory phasing and frozen periods to cause quarterly volatility, with stabilization by end of FY26.
Management guidance revenueDiabetes segment to sustain double-digit growth
Driven by insulin portfolio (Toujeo, Soliqua) and expansion in public sector, though market dynamics remain volatile.
Management guidance growthNo new product launches in FY26
Focus remains on maximizing current portfolio (Soliqua, Toujeo) and real-world evidence publications.
Management guidance otherKey Risks
Partnership revenue volatility
Quarterly fluctuations due to inventory phasing and frozen periods may persist through FY26, obscuring underlying growth.
high · management_commentaryCompetitive pressure in institutional business
Aggressive discounting by competitors in certain accounts and institutional business is impacting partnership sales.
medium · analyst_questionGLP-1 market invasion
Rapid growth of GLP-1 drugs could cannibalize insulin sales, though Soliqua (GLP-1/insulin combo) may mitigate.
medium · data_observationNotable Quotes
We are not allowed to give the details by business between the partnership in terms of margin.
The fluctuation will continue in 2026. By end of 2026 we will stabilize this partnership.
We have a lot to do with the current portfolio. Soliqua is just one year old in the game.
Frequently Asked Questions
What was Sanofi India's revenue in Q3 FY26?
Sanofi India reported revenue of ₹1,511 Cr in Q3 FY26, representing a — change compared to the same quarter last year.
What guidance did Sanofi India management give for FY27?
Partnership revenue fluctuations to continue through FY26: Management expects inventory phasing and frozen periods to cause quarterly volatility, with stabilization by end of FY26. Diabetes segment to sustain double-digit growth: Driven by insulin portfolio (Toujeo, Soliqua) and expansion in public sector, though market dynamics remain volatile. No new product launches in FY26: Focus remains on maximizing current portfolio (Soliqua, Toujeo) and real-world evidence publications.
What are the key risks for Sanofi India in FY27?
Key risks include Partnership revenue volatility — Quarterly fluctuations due to inventory phasing and frozen periods may persist through FY26, obscuring underlying growth.; Competitive pressure in institutional business — Aggressive discounting by competitors in certain accounts and institutional business is impacting partnership sales.; GLP-1 market invasion — Rapid growth of GLP-1 drugs could cannibalize insulin sales, though Soliqua (GLP-1/insulin combo) may mitigate..
Did Sanofi India meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Sanofi India Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.